Panasonic Healthcare Holdings agreed Wednesday to acquire the diabetes devices business of German conglomerate Bayer for 1.02 billion euros.
Bayer Diabetes Care or BDC, is one of the leading providers of blood glucose monitoring systems to people with diabetes and healthcare professionals around the world.
The company expects to close the deal in the first quarter of 2016, subject to customary closing conditions, including relevant antitrust clearance.
“We are confident that the sale of our Diabetes Care business to our long-standing partner Panasonic Healthcare, with the strong backing of KKR, will support the long-term sustainability of this portfolio,” said Werner Baumann, member of the Board of Management of Bayer AG and CEO of Bayer HealthCare.
Full content: Blouin News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Electrolux Fined €44.5 Million in French Antitrust Case
Dec 19, 2024 by
CPI
Indian Antitrust Body Raids Alcohol Giants Amid Price Collusion Probe
Dec 19, 2024 by
CPI
Attorneys Seek $525 Million in Fees in NCAA Settlement Case
Dec 19, 2024 by
CPI
Italy’s Competition Watchdog Ends Investigation into Booking.com
Dec 19, 2024 by
CPI
Minnesota Judge Approves $2.4 Million Hormel Settlement in Antitrust Case
Dec 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand